Skip to main content
NIH funding notice PAR-18-605

Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional)

Closed on April 11, 2019.

Posted
January 30, 2018
Close date
April 11, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,564,407 in first-year total cost, median $782,204.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 BDCN-J (55)]2

Most frequent institutions

  1. ALBERT EINSTEIN COLLEGE OF MEDICINE1
  2. UNIVERSITY OF ROCHESTER1
Competing awards under PAR-18-605 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia1R01CA240360-01A1COLE, PETER D.SUSSMAN, ELYSE SWAGSHUL, MARK EALBERT EINSTEIN COLLEGE OF MEDICINE, NY$931,687ZRG1
2019Translational Neuroscience Approaches to Cancer-Related Cognitive Impairment: Measurement, Mechanisms, and Function1R01CA231014-01A1JANELSINS, MICHELLE CUNIVERSITY OF ROCHESTER, NY$632,720ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.